Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129813 | 0.89 | L3MBTL1 (0.32) | PIK3CA | |
| SCHEMBL1286289 | 0.88 | USP2 (0.32) | PIK3CA | |
| SCHEMBL1619293 | 0.86 | ALDH1A1 (0.35) | — | |
| SCHEMBL101563 | 0.83 | ALDH1A1 (0.40) | RAB9A | |
| SCHEMBL97446 | 0.83 | ALDH1A1 (0.40) | RAB9A | |
| SCHEMBL1679227 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL130580 | 0.80 | GSK3B (0.39) | — | |
| SCHEMBL1677201 | 0.80 | MAPT (0.31) | RAB9A | |
| SCHEMBL16556645 | 0.79 | CYP1A2 (0.33) | — | |
| SCHEMBL131532 | 0.79 | YTHDC1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | PNP, TYMP, DPYD | PIK3CA 1539/4885RAB9A 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.